Recorded Q3'24 consolidated revenue of KRW 1.2 trillion Recorded Q3'24 consolidated operating profit of KRW 338.6 billion Continued business expansion through strong competitive edge in speed and execution INCHEON, South Korea , Oct.
23, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the third quarter of fiscal year 2024. "We made steady progress this quarter, achieving consistent performance across all our plants while expanding our capabilities to better address the needs of our clients," said John Rim , CEO and President of Samsung Biologics.
"As we continue to enhance our CMO technologies and introduce new CDO platforms, we remain committed to providing high-quality, innovative solutions that are essential for development and manufacturing success maximized through our unique operational excellence initiatives. This will reinforce our efforts to deepen our global partnerships and enhance the value we offer to our clients." THIRD QUARTER 2024 RESULTS In the third quarter, consolidated revenue reached KRW 1.
2 trillion , marking a 15% increase compared to the previous year, while operating profit stood at KRW 338.6 billion . On a standalone basis, the company achieved revenue of KRW 1.
1 trillion , while operating profit reached KRW 444.7 billion . The quarter's results were buoyed by the contribution of the newest Plant 4 and the full utilization of Plants 1 t.